Literature DB >> 16943438

Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform.

Sang Soo Kim1, Liu Cao, Sung-Chul Lim, Cuiling Li, Rui-Hong Wang, Xiaoling Xu, Richard Bachelier, Chu-Xia Deng.   

Abstract

Alternative splicing in the BRCA1 locus generates multiple protein products including BRCA1-Delta11, which is identical to the BRCA1 full-length isoform (BRCA1-FL) except for the absence of exon 11. Mutation analysis using gene targeting to create null mutations or disrupt BRCA-FL has provided much of our understanding of BRCA1 functions; however, targeted mutation of specific short forms of BRCA1 has not been reported. To understand the physiologic functions of BRCA1-Delta11, we used a knock-in approach that blocks alternative splicing between exons 10 and 12 to prevent the formation of this form of BRCA1. We showed that homozygous mutant mice (Brca1(FL/FL)) were born at a Mendelian ratio without obvious developmental defects. However, the majority of Brca1(FL/FL) female mice showed mammary gland abnormalities and uterine hyperplasia after one year of age with spontaneous tumor formation. Cultured Brca1(FL/FL) cells exhibited abnormal centrosome amplification and reduction of G(1) population that was accompanied by accumulation of cyclin E and cyclin A. Accumulation of cyclin E was also found in epithelial layers of dilated ducts and hyperproliferative lobular regions in the mammary glands of Brca1(FL/FL) mice. These observations provide evidence that BRCA1 splicing variants are involved in BRCA1 functions in modulating G(1)/S transition, centrosome duplication, and repressing tumor formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943438      PMCID: PMC1592852          DOI: 10.1128/MCB.00796-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

1.  Identification of a gamma-tubulin-binding domain in BRCA1.

Authors:  L C Hsu; T P Doan; R L White
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

2.  Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci.

Authors:  L J Huber; T W Yang; C J Sarkisian; S R Master; C X Deng; L A Chodosh
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 3.  Roles of BRCA1 in centrosome duplication.

Authors:  Chu-Xia Deng
Journal:  Oncogene       Date:  2002-09-09       Impact factor: 9.867

4.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

Authors:  X Xu; W Qiao; S P Linke; L Cao; W M Li; P A Furth; C C Harris; C X Deng
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

Review 5.  Lessons learned from BRCA1 and BRCA2.

Authors:  L Zheng; S Li; T G Boyer; W H Lee
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

6.  Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.

Authors:  Yanfen Hu; Sagar Ghosh; Asma Amleh; Wei Yue; Yunzhe Lu; Adam Katz; Rong Li
Journal:  Oncogene       Date:  2005-12-15       Impact factor: 9.867

7.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 8.  Tumor formation in Brca1 conditional mutant mice.

Authors:  Chu-Xia Deng
Journal:  Environ Mol Mutagen       Date:  2002       Impact factor: 3.216

Review 9.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

10.  Fibroblast growth factor receptor 3 is a negative regulator of bone growth.

Authors:  C Deng; A Wynshaw-Boris; F Zhou; A Kuo; P Leder
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

View more
  16 in total

1.  SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues.

Authors:  Sungpil Yoon; Young-Su Yi; Sang Soo Kim; Ju-Hwa Kim; Won Sang Park; Suk Woo Nam
Journal:  Tumour Biol       Date:  2011-11-12

2.  Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.

Authors:  Huchun Li; Masayuki Sekine; Nadine Tung; Hava Karsenty Avraham
Journal:  Mol Cancer Res       Date:  2010-03-09       Impact factor: 5.852

3.  Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Hye Jung Baek; Sung-Chul Lim; Cuiling Li; Rui-Hong Wang; Xiaoling Xu; Kwan Ho Cho; Chu-Xia Deng
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Consistency of variant interpretations among bioinformaticians and clinical geneticists in hereditary cancer panels.

Authors:  Nihat Bugra Agaoglu; Busra Unal; Ozlem Akgun Dogan; Martin Orlinov Kanev; Payam Zolfagharian; Sebnem Ozemri Sag; Sehime Gulsun Temel; Levent Doganay
Journal:  Eur J Hum Genet       Date:  2022-02-08       Impact factor: 4.246

5.  Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis.

Authors:  Hye Jung Baek; Sung Chul Lim; Krit Kitisin; Wilma Jogunoori; Yi Tang; M Blair Marshall; Bibhuti Mishra; Tae Hyun Kim; Kwan Ho Cho; Sang Soo Kim; Lopa Mishra
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

6.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

7.  Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling.

Authors:  N M Reddy; S R Kleeberger; J H Bream; P G Fallon; T W Kensler; M Yamamoto; S P Reddy
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

8.  A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.

Authors:  Ying Liu; Hai-Yun Yen; Theresa Austria; Jonas Pettersson; Janos Peti-Peterdi; Robert Maxson; Martin Widschwendter; Louis Dubeau
Journal:  EBioMedicine       Date:  2015-09-09       Impact factor: 8.143

Review 9.  Preclinical mouse models for BRCA1-associated breast cancer.

Authors:  R M Drost; J Jonkers
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

Review 10.  BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?

Authors:  Li Wang; Li-Jun Di
Journal:  Int J Biol Sci       Date:  2014-05-14       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.